Compared to the meta-analysis by Rodrigo et al., which only compared high PD-L1 expression(PD-L1 ≥10%) in R/M HNSCC patients using immunotherapy versus SOC, our study stratified PD-L1 expression levels and identified the optimal immunotherapy regimens (33). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.